It’s not clear that this drug is safe in the long term so why would NICE approve it to be provided for free to potentially millions of people?
It is claimed Mounjaro, the brand name of tirzepatide, is more effective than semaglutide, known as Ozempic and Wegovy.
Writing for the Daily Mail, Dr. Renée Hoenderkamp expressed concerns that not only will the availability of the drugs at taxpayers’ expense undermine the idea that people should take responsibility for their own lifestyle choices, but it will add to the strain on the already overstretched NHS Budget.
The principle – that the NHS will bankroll irresponsible behaviour and thereby encourage it – is a troubling one, she said.
Mounjaro which costs £122 per month will initially be offered to 222,000 people, a fraction of the 3.4 million in Britain who are classified as obese. “Once the Mounjaro jab is prescribed it will be difficult, if not impossible, for the NHS to keep a lid on the numbers,” Dr. Hoenderkamp said.
If the injections were given to 3.4 million people, that would equate to nearly £415 million per month.
Additionally, she said, “it is not clear that the drug is safe in the long term and its manufacturer has yet to share full details of the research it has funded so far. Side-effects may take years, even decades to emerge, which means that this step amounts to an expensive leap into the unknown.”
So why are the NHS embarking on this madness?...<<<Read More>>>...